STOKE THERAPEUTICS INC (STOK)
US86150R1077 - Common Stock
We assign a fundamental rating of 3 out of 10 to STOK. STOK was compared to 587 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for STOK as it has an excellent financial health rating, but there are worries on the profitability. STOK does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
STOK had negative earnings in the past year.
In the past year STOK has reported a negative cash flow from operations.
STOK had negative earnings in each of the past 5 years.
STOK had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
STOK has a Return On Assets (-52.89%) which is comparable to the rest of the industry.
STOK's Return On Equity of -77.33% is in line compared to the rest of the industry. STOK outperforms 52.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.89% | ||
| ROE | -77.33% | ||
| ROIC | N/A |
ROA(3y)-40.41%
ROA(5y)-30.58%
ROE(3y)-53.24%
ROE(5y)-38.47%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for STOK so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
STOK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, STOK has more shares outstanding
Compared to 5 years ago, STOK has more shares outstanding
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
STOK has an Altman-Z score of 2.90. This is not the best score and indicates that STOK is in the grey zone with still only limited risk for bankruptcy at the moment.
STOK's Altman-Z score of 2.90 is fine compared to the rest of the industry. STOK outperforms 73.33% of its industry peers.
There is no outstanding debt for STOK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 2.9 |
ROIC/WACCN/A
WACC9.02%
2.3 Liquidity
STOK has a Current Ratio of 5.43. This indicates that STOK is financially healthy and has no problem in meeting its short term obligations.
STOK has a Current ratio of 5.43. This is comparable to the rest of the industry: STOK outperforms 57.27% of its industry peers.
A Quick Ratio of 5.43 indicates that STOK has no problem at all paying its short term obligations.
STOK has a Quick ratio (5.43) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.43 | ||
| Quick Ratio | 5.43 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 2.27% over the past year.
The Revenue for STOK has decreased by -46.10% in the past year. This is quite bad
EPS 1Y (TTM)2.27%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-7.55%
Revenue 1Y (TTM)-46.1%
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2Q-18.17%
3.2 Future
Based on estimates for the next years, STOK will show a quite strong growth in Earnings Per Share. The EPS will grow by 16.36% on average per year.
Based on estimates for the next years, STOK will show a very strong growth in Revenue. The Revenue will grow by 78.84% on average per year.
EPS Next Y-0.92%
EPS Next 2Y-6.03%
EPS Next 3Y0.19%
EPS Next 5Y16.36%
Revenue Next Year28.25%
Revenue Next 2Y27.9%
Revenue Next 3Y51.75%
Revenue Next 5Y78.84%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for STOK. In the last year negative earnings were reported.
Also next year STOK is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.03%
EPS Next 3Y0.19%
5. Dividend
5.1 Amount
No dividends for STOK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
STOKE THERAPEUTICS INC
NASDAQ:STOK (5/17/2024, 7:00:01 PM)
After market: 13.9 0 (0%)13.9
-0.13 (-0.93%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap724.47M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -52.89% | ||
| ROE | -77.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.04
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.43 | ||
| Quick Ratio | 5.43 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)2.27%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-0.92%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-46.1%
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y